ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We studied nine single nucleotide polymorphisms (SNPs) located in CTNNB1 (β-catenin) [rs4533622, rs2953], APC (rs11954856, rs351771, rs459552), and AXIN2 (rs4074947, rs7224837, rs3923087, rs2240308) in women with ovarian cancer without BRCA1/BRCA2 mutations (n = 228) and controls (n = 282).
|
24078348 |
2014 |
ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
In search of this transformation mechanism in human cancer cells, we identified breast and ovarian tumor lines with upregulation of the uncomplexed transcriptionally active form of beta-catenin without mutations afflicting downstream components.
|
15542433 |
2004 |
ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
This revealed 10/63 (16%) endometrioid ovarian tumours with activating mutations of the beta-catenin gene.
|
10417756 |
1999 |
ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Nuclear immunoreactivities for beta -catenin and CTNNB1 mutations were restricted to independent uterine and ovarian tumors and were absent in all of the metastatic tumors, providing direct evidence for a divergence of molecular oncogenetic mechanisms in the subset of synchronous endometrioid carcinomas.
|
16021566 |
2005 |
ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic activation of the Wnt signaling pathway is common in cancers, but mutation of beta-catenin in ovarian cancer is rare.
|
19957335 |
2010 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/β-Catenin Signaling in Ovarian Cancer.
|
31193124 |
2019 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.
|
22232518 |
2012 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our study identifies activated Wnt signalling to be a marker for precursor lesions of OC and successfully develops a mouse model that mimics the earliest events in pathogenesis of OC by constitutively activating βcatenin.
|
27588493 |
2016 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our work highlights the therapeutic value of inhibiting Wnt/β-catenin in ovarian cancer.
|
28090074 |
2017 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Collectively, these data indicated that β-catenin is involved in Twist2-induced EMT in ovarian cancer.
|
24244294 |
2013 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
These results suggested that miR-214 may serve as a tumor suppressor of ovarian cancer by targeting the β-catenin pathway.
|
29486472 |
2018 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer.
|
26341496 |
2016 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
These results uncover β-catenin as a critical factor in promoting ovarian cancer aggressiveness and a new mechanism linking between β-catenin and miRNA downregulation underlying this process.
|
28650464 |
2017 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Thus, β-catenin could be a potential therapeutic target for the therapy of cisplatin-resistant ovarian cancer.
|
25211326 |
2015 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin.
|
31653698 |
2019 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
β-Catenin knockdown blocked tumor growth and peritoneal metastasis in an OC xenograft model.
|
24954508 |
2015 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Taken together, this study showed that Annexin A2 inhibition suppresses proliferation and invasion in ovarian cancer via β-catenin/EMT, proposing the potential role of Annexin A2 in the prevention and treatment of ovarian cancer.
|
28440436 |
2017 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
CTD_human |
Effect of downregulated β-catenin on cell proliferative activity, the sensitivity to chemotherapy drug and tumorigenicity of ovarian cancer cells.
|
22000491 |
2011 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
MGD |
|
|
|
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours.
|
16479254 |
2006 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our work also provides a proper understanding on the regulation of Wnt/β-catenin pathway in ovarian cancer.
|
30572097 |
2019 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
CXC chemokine receptor 4 plays a critical role in the metastasis of human ovarian cancer possibly through modulating the Wnt/β-catenin pathway.
|
21738044 |
2011 |
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of β-catenin.
|
31685298 |
2019 |
ovarian neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Further, the expression of SOX9, β-catenin, and c-Myc in OC tissues was upregulated and inversely correlated with miR-34c expression, indicating that rescuing miR-34c expression, thus to inhibit SOX9, β-catenin, and c-Myc expression presents a promising strategy of reducing the chemoresistance of the OC cell to DDP.
|
30537410 |
2019 |